[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Arcus Biosciences Inc (RCUS)

Arcus Biosciences Inc (RCUS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,203,540
  • Shares Outstanding, K 125,629
  • Annual Sales, $ 247,000 K
  • Annual Income, $ -353,000 K
  • EBIT $ -386 M
  • EBITDA $ -389 M
  • 60-Month Beta 0.86
  • Price/Sales 12.78
  • Price/Cash Flow N/A
  • Price/Book 4.30

Options Overview Details

View History
  • Implied Volatility 71.66% (-12.93%)
  • Historical Volatility 59.40%
  • IV Percentile 7%
  • IV Rank 7.08%
  • IV High 220.54% on 08/08/25
  • IV Low 60.32% on 12/22/25
  • Expected Move (DTE 18) 3.72 (14.65%)
  • Put/Call Vol Ratio 0.01
  • Today's Volume 73
  • Volume Avg (30-Day) 433
  • Put/Call OI Ratio 0.43
  • Today's Open Interest 7,265
  • Open Int (30-Day) 8,982
  • Expected Range 21.69 to 29.13

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.92
  • Number of Estimates 4
  • High Estimate $-0.85
  • Low Estimate $-1.01
  • Prior Year $-1.14
  • Growth Rate Est. (year over year) +19.30%

Price Performance

See More
Period Period Low Period High Performance
1-Month
20.00 +26.20%
on 03/30/26
28.72 -12.12%
on 04/22/26
+4.96 (+24.46%)
since 03/27/26
3-Month
18.51 +36.32%
on 02/23/26
28.72 -12.12%
on 04/22/26
+2.25 (+9.79%)
since 01/27/26
52-Week
7.06 +257.51%
on 05/07/25
28.72 -12.12%
on 04/22/26
+16.94 (+204.10%)
since 04/25/25

Most Recent Stories

More News
Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory...

RCUS : 25.24 (-1.02%)
Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2026 Financial Results and Pipeline Updates

Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer and inflammatory and...

RCUS : 25.24 (-1.02%)
Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory...

RCUS : 25.24 (-1.02%)
Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory...

RCUS : 25.24 (-1.02%)
Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory...

RCUS : 25.24 (-1.02%)
Arcus Biosciences to Participate in Two Upcoming Investor Conferences

Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer and inflammatory and...

RCUS : 25.24 (-1.02%)
Arcus Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides a Pipeline Update

Updated data for casdatifan in late-line kidney cancer demonstrated median progression-free survival (PFS) of 15.1 months and a confirmed overall response rate (cORR) of 45% for the 100mg once-daily (QD)...

RCUS : 25.24 (-1.02%)
Arcus Presents New Data for its HIF-2a Inhibitor Casdatifan, Which Showed Progression-Free Survival Beyond One Year in Late-Line Kidney Cancer

Median progression-free survival (mPFS) was 15.1 months, and the confirmed overall response rate (cORR) increased to 45% for the 100mg QD (once daily) tablet cohort in an updated analysis of the ARC-20...

RCUS : 25.24 (-1.02%)
Arcus Biosciences to Host Conference Call to Discuss Fourth-Quarter and Full-Year 2025 Financial Results and Pipeline Updates

Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer and inflammatory and...

RCUS : 25.24 (-1.02%)
Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory...

RCUS : 25.24 (-1.02%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Arcus Biosciences is a biopharmaceutical company. It focused on creating innovative cancer immunotherapies. The company's product portfolio includes AB928, AB122, AB154 and AB680. AB928 which is in its final phase is a potent and selective dual antagonist of the adenosine receptors. AB122 which is in...

See More

Key Turning Points

3rd Resistance Point 27.41
2nd Resistance Point 26.66
1st Resistance Point 26.08
Last Price 25.24
1st Support Level 24.75
2nd Support Level 24.00
3rd Support Level 23.42

See More

52-Week High 28.72
Last Price 25.24
Fibonacci 61.8% 20.45
Fibonacci 50% 17.89
Fibonacci 38.2% 15.33
52-Week Low 7.06

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.